Gopi Battineni, Nalini Chintalapudi, Francesco Amenta
{"title":"Machine Learning Driven by Magnetic Resonance Imaging for the Classification of Alzheimer Disease Progression: Systematic Review and Meta-Analysis.","authors":"Gopi Battineni, Nalini Chintalapudi, Francesco Amenta","doi":"10.2196/59370","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To diagnose Alzheimer disease (AD), individuals are classified according to the severity of their cognitive impairment. There are currently no specific causes or conditions for this disease.</p><p><strong>Objective: </strong>The purpose of this systematic review and meta-analysis was to assess AD prevalence across different stages using machine learning (ML) approaches comprehensively.</p><p><strong>Methods: </strong>The selection of papers was conducted in 3 phases, as per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 2020 guidelines: identification, screening, and final inclusion. The final analysis included 24 papers that met the criteria. The selection of ML approaches for AD diagnosis was rigorously based on their relevance to the investigation. The prevalence of patients with AD at 2, 3, 4, and 6 stages was illustrated through the use of forest plots.</p><p><strong>Results: </strong>The prevalence rate for both cognitively normal (CN) and AD across 6 studies was 49.28% (95% CI 46.12%-52.45%; P=.32). The prevalence estimate for the 3 stages of cognitive impairment (CN, mild cognitive impairment, and AD) is 29.75% (95% CI 25.11%-34.84%, P<.001). Among 5 studies with 14,839 participants, the analysis of 4 stages (nondemented, moderately demented, mildly demented, and AD) found an overall prevalence of 13.13% (95% CI 3.75%-36.66%; P<.001). In addition, 4 studies involving 3819 participants estimated the prevalence of 6 stages (CN, significant memory concern, early mild cognitive impairment, mild cognitive impairment, late mild cognitive impairment, and AD), yielding a prevalence of 23.75% (95% CI 12.22%-41.12%; P<.001).</p><p><strong>Conclusions: </strong>The significant heterogeneity observed across studies reveals that demographic and setting characteristics are responsible for the impact on AD prevalence estimates. This study shows how ML approaches can be used to describe AD prevalence across different stages, which provides valuable insights for future research.</p>","PeriodicalId":36245,"journal":{"name":"JMIR Aging","volume":"7 ","pages":"e59370"},"PeriodicalIF":5.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704653/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/59370","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To diagnose Alzheimer disease (AD), individuals are classified according to the severity of their cognitive impairment. There are currently no specific causes or conditions for this disease.
Objective: The purpose of this systematic review and meta-analysis was to assess AD prevalence across different stages using machine learning (ML) approaches comprehensively.
Methods: The selection of papers was conducted in 3 phases, as per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 2020 guidelines: identification, screening, and final inclusion. The final analysis included 24 papers that met the criteria. The selection of ML approaches for AD diagnosis was rigorously based on their relevance to the investigation. The prevalence of patients with AD at 2, 3, 4, and 6 stages was illustrated through the use of forest plots.
Results: The prevalence rate for both cognitively normal (CN) and AD across 6 studies was 49.28% (95% CI 46.12%-52.45%; P=.32). The prevalence estimate for the 3 stages of cognitive impairment (CN, mild cognitive impairment, and AD) is 29.75% (95% CI 25.11%-34.84%, P<.001). Among 5 studies with 14,839 participants, the analysis of 4 stages (nondemented, moderately demented, mildly demented, and AD) found an overall prevalence of 13.13% (95% CI 3.75%-36.66%; P<.001). In addition, 4 studies involving 3819 participants estimated the prevalence of 6 stages (CN, significant memory concern, early mild cognitive impairment, mild cognitive impairment, late mild cognitive impairment, and AD), yielding a prevalence of 23.75% (95% CI 12.22%-41.12%; P<.001).
Conclusions: The significant heterogeneity observed across studies reveals that demographic and setting characteristics are responsible for the impact on AD prevalence estimates. This study shows how ML approaches can be used to describe AD prevalence across different stages, which provides valuable insights for future research.
背景:为了诊断阿尔茨海默病(AD),个体根据其认知障碍的严重程度进行分类。目前还没有这种疾病的具体原因或条件。目的:本系统综述和荟萃分析的目的是利用机器学习(ML)方法全面评估AD在不同阶段的患病率。方法:根据PRISMA(首选报告项目用于系统评价和荟萃分析)2020指南,论文的选择分为三个阶段:识别、筛选和最终纳入。最终的分析包括24篇符合标准的论文。对AD诊断的ML方法的选择严格基于它们与调查的相关性。通过使用森林样地说明AD患者在2、3、4和6期的患病率。结果:6项研究中认知正常(CN)和AD的患病率为49.28% (95% CI 46.12%-52.45%;P =收)。三个阶段认知障碍(CN、轻度认知障碍和AD)的患病率估计为29.75% (95% CI 25.11%-34.84%)。结论:研究中观察到的显著异质性表明,人口统计学和环境特征对AD患病率估计有影响。该研究显示了机器学习方法如何用于描述不同阶段的AD患病率,这为未来的研究提供了有价值的见解。